Pharmacyclics pullback makes it attractive, says Brean Capital Brean Capital said the pullback in Pharmacyclics had made it one of the most attractive investment opportunities in its space. The firm cited positive Phase 3 studies for ibrutinib which highlighted its potential as a front line therapy in the next 3-4 years. Shares are Buy rated with an $80 price target.
Pharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).